Table 4:

T-cell-specific responses in patients positive for the HLA-A2 serotype by dose

	Influenza (control)	PSA peptide	MUC1	Brachyury	ANO7	HIV peptide
3 mg/kg
Patient 5
Before	1/7595	<1/200000	<1/200 000	NA	NA	<1/200000
Day 102	1/22 222	<1/200000	<1/200000	NA	NA	<1/200000
Patient 6
Before	1/9434	<1/200000	<1/200 000	1/120000	NA	<1/200000
Day 78	1/16667	<1/200000	1/100000	1/46154	NA	<1/200000
Patient 7
Before	1/35294	<1/200000	<1/200 000	NA	NA	<1/200000
Day 70	1/17143	<1/200000	<1/200000	NA	NA	<1/200000
5 mg/kg
Patient 8
Before	1/7692	<1/200000	<1/200 000	1/33333	NA	<1/200000
Day 93	1/10 638	<1/200000	<1/200000	<1/200000	NA	<1/200000
Patient 10
Before	1/3226	<1/200000	<1/200 000	<1/200000	NA	<1/200000
Day 118	1/4615	<1/200000	1/85714	<1/200000	NA	<1/200000
Patient 11
Before	1/50000	<1/200000	<1/200 000	NA	NA	<1/200000
Day 78	1/16667	<1/200000	<1/100000	NA	NA	<1/200000
10 mg/kg
Patient 20
Before	1/25000	<1/200000	<1/200 000	<1/200000	<1/200 000	<1/200000
Day 94	1/30 000	1/150000	1/66 667	1/46154	1/26087	<1/200000
Patient 21
Before	1/62 500	<1/200000	<1/200 000	<1/200000	<1/200 000	<1/200000
Day 97	1/15625	1/40000	1/100000	1/41667	1/125000	<1/200000
Patient 22
Before	1/19231	1/29412	<1/200 000	1/83333	<1/200 000	<1/200000
Day 78	1/10714	1/46154	<1/200000	<1/200000	<1/200 000	<1/200000

Dose refers to dose of ipilimumab. PSA=prostate-specific antigen.